ライフサイエンスコーパス: cannabinoid receptor

1 t affinity for the centrally expressed CB(1) cannabinoid receptor.

2 endogenous allosteric enhancer of the CB(1) cannabinoid receptor.

3 PR55 has been postulated to serve as a novel cannabinoid receptor.

4 ts of 2-AG are mediated by G-protein-coupled cannabinoid receptors.

5 gement of the enteric nervous system through cannabinoid receptors.

6 es of these SCs retain their activity at the cannabinoid receptors.

7 them (14b) being selective versus classical cannabinoid receptors.

8 rostaglandin synthesis than by activation of cannabinoid receptors.

9 olites of these SCs retain their activity at cannabinoid receptors.

10 ical effects through their interactions with cannabinoid receptors.

11 nists (21) is fully selective versus classic cannabinoid receptors.

12 ound to require intact signaling through CB2 cannabinoid receptors.

13 early developmental stress and is dense with cannabinoid receptors.

14 nvestigate PPAR agonists for activity at the cannabinoid receptors.

15 rol (2-AG), and controls its availability at cannabinoid receptors.

16 erate through cell surface G-protein-coupled cannabinoid receptors.

17 , which releases 2-AG, and presynaptic CB(1) cannabinoid receptors.

18 be high affinity ligands for the CB1 and CB2 cannabinoid receptors.

19 y arachidonic acid, which has no activity on cannabinoid receptors.

20 odels via 2-AG-dependent activation of CB(1) cannabinoid receptors.

21 e periphery and interact with peripheral CB2 cannabinoid receptors.

22 Cannabinoid receptor 1 (CB(1)) is a G-protein-coupled re

23 hin intron 2 of the CNR1 gene, which encodes cannabinoid receptor 1 (CB(1)), have been associated wit

24 The cannabinoid receptor 1 (CB(1)R) is required for body wei

25 in-2-yl)phenyl)urea (PSNCBAM-1, 2) bound the cannabinoid receptor 1 (CB1) and antagonized G protein c

26 gated the effect of treatment of mice with a cannabinoid receptor 1 (CB1) antagonist on Diet-Induced

27 Cannabinoid receptor 1 (CB1) antagonists are potentially

28 Although cannabinoid receptor 1 (CB1) antagonists have been shown

29 Agonists of the cannabinoid receptor 1 (CB1) have been suggested as poss

30 Antagonists of cannabinoid receptor 1 (CB1) have potential for the trea

31 Structures of the cannabinoid receptor 1 (CB1) in complex with an "ultrapo

32 The cannabinoid receptor 1 (CB1) is a G protein-coupled rece

33 The cannabinoid receptor 1 (CB1) is an inhibitory G protein-

34 are expressed in the MHb and MSDB, and that cannabinoid receptor 1 (CB1) is expressed in the MSDB.

35 The cannabinoid receptor 1 (CB1) is the principal target of

36 Cannabinoid receptor 1 (CB1) is the principal target of

37 Cannabinoid receptor 1 (CB1) mediates the functional res

38 We show that anxiolysis depends on intact cannabinoid receptor 1 (CB1) receptors on forebrain GABA

39 -enhancing and analgesic effects through the cannabinoid receptor 1 (CB1), a G protein-coupled recept

40 The cannabinoid receptor 1 (CB1), a member of the class A G

41 diated by the endocannabinoid anandamide and cannabinoid receptor 1 (CB1), was significantly attenuat

42 nt on metabotropic glutamate receptor 5, and cannabinoid receptor 1 (CB1).

43 ids modulate intestinal permeability through cannabinoid receptor 1 (CB1).

44 n-coupled receptor (GPCR) 55 (GPR55) and the cannabinoid receptor 1 (CB1R) are co-expressed in many t

45 rincipal cortical neurons leads to defective cannabinoid receptor 1 (CB1R) dependent synaptic plastic

46 Cannabinoid receptor 1 (CB1R) is critical for the centra

47 nnabinoid system (ECS) through antagonism of cannabinoid receptor 1 (CB1R) reduces food intake and im

48 protein-coupled receptors (GPCRs), including cannabinoid receptor 1 (CB1R), desensitization has been

49 Here by studying the cannabinoid receptor 1 (CB1R), we identify ligand-specif

50 interactor with the intracellular region of Cannabinoid Receptor 1 (CB1R, also known as Cnr1 or CB1)

51 n, but not endodermal specification: loss of cannabinoid receptor 1 (cnr1) and cnr2 activity leads to

52 Treatment of ob/ob (obese) mice with a cannabinoid receptor 1 (Cnr1) antagonist reduces food in

53 se 1 (DNMT1), delta-opioid receptor (OPRD1), cannabinoid receptor 1 (CNR1), and catechol-o-methyltran

54 Levels of cannabinoid receptor 1 (CNR1), DNA (cytosine-5-)-methylt

55 nt brain functions and it is mediated by the cannabinoid receptor 1 (CNR1), which is encoded by the C

56 ciency is not fully abrogated by the inverse cannabinoid receptor 1 agonist SR141716 (Rimonabant) sug

57 Mixed cannabinoid receptor 1 and 2 (CB1 and CB2) agonists such

58 ycerol (2-AG) is acting as a full agonist of cannabinoid receptor 1 and 2.

59 M PPARalpha antagonist GW6471, but not 1 muM cannabinoid receptor 1 antagonist SR141716A, produced a

60 In contrast, AM251 (10 mum), a cannabinoid receptor 1 antagonist, did not impair visual

61 augmentation of AEA signaling and via direct cannabinoid receptor 1 stimulation with Delta(9)-tetrahy

62 As both neurons and glial cells express cannabinoid receptor 1, genetic vulnerability could infl

63 bis constituent and partial agonist of brain cannabinoid receptor 1.

64 te the effects of blocking TRPV1 or specific cannabinoid receptors 1 (CB1r) and 2 (CB2r) on periodont

65 The endocannabinoid system comprises cannabinoid receptors 1 and 2 (CB1 and CB2), their endog

66 NADA is also an agonist of cannabinoid receptors 1 and 2.

67 Here, we investigated structural changes in cannabinoid-receptor 1 (CB(1))-mediated long-term depres

68 Inhibition of the cannabinoid receptor-1 (CB1) by the antagonist rimonaban

69 GLP-1R agonism, cannabinoid receptor-1 (CB1-R) antagonism, or vehicle wa

70 teration of glucose homeostasis dependent on cannabinoid receptor-1 (CB1R) activation.

71 itron emission tomography scan each with the cannabinoid receptor-1 (CB1R) selective radiotracer [(11

72 Signaling through cannabinoid receptor 2 (CB(2)) dampens immune activation

73 xy-benzo(c) chromen-6-one), a cannabilactone cannabinoid receptor 2 (CB2) agonist, suppresses chemoth

74 t CXCR4 can form an induced heterodimer with cannabinoid receptor 2 (CB2) in human breast and prostat

75 Cannabinoid receptor 2 (CB2) is highly expressed in immu

76 Cannabinoid receptor 2 (CB2) is predominantly expressed

77 We investigated the role of the cannabinoid receptor 2 (CB2), an important modulator of

78 we uncover a role for AEA and its receptor, cannabinoid receptor 2 (CB2), in the regulation of immun

79 rachidonoylglycerol (2-AG) and its receptor, cannabinoid receptor 2 (CB2), play a role in the establi

80 ypical GPCR present on these cells, i.e. the cannabinoid receptor 2 (CB2), was selected for pharmacol

81 ol (2-AG), and elucidated a hitherto unknown cannabinoid receptor 2 (CB2)-mediated regulatory role of

82 Administration of cannabinoid receptor 2 (CB2R) agonists in inflammatory a

83 icle by Rom et al which shows that selective cannabinoid receptor 2 activation in leukocytes decrease

84 t time, that transient administration of the cannabinoid receptor 2 antagonist AM630 (10 mg/kg) or in

85 Pretreatment of anterior segments with 1 muM cannabinoid receptor 2 antagonist SR144528 and 1 muM PPA

86 Cannabinoid receptor 2 deficiency exacerbates inflammati

87 The discovery of functional cannabinoid receptors 2 (CB2Rs) in brain suggests a pote

88 perties by virtue of its ability to activate cannabinoid receptor-2 (CB-2) expressed on immune cells.

89 nflammatory IL-10 cytokines, in part through cannabinoid receptor-2 activation.

90 1 receptor-dependent manner--suggesting that cannabinoid receptor activation modifies timing behavior

91 e molecular cascade coupling agonist-induced cannabinoid receptor activation to insulin release remai

92 abinoid reporter system, which monitored the cannabinoid receptor activation, was compared to the qua

93 ium-activated potassium (SK) channel and CB1 cannabinoid receptor activation.

94 glial Slit2 production on cell-type-specific cannabinoid receptor activation.

95 sired psychoactive effects of neuronal CB(1) cannabinoid receptor activation.

96 elf-administration (SA), using the synthetic cannabinoid receptor agonist WIN55,212-2 (WIN), in order

97 The cannabinoid receptor agonist WIN55212-2 (10-30 ng/side),

98 In Caenorhabditis elegans, the endogenous cannabinoid receptor agonist, 2-arachidonoylglycerol (2-

99 The cannabinoid receptor agonist, Delta(9)-tetrahydrocannabi

100 of several compounds as potent and selective cannabinoid receptor agonists (20, hCB(2)K(i) = 2.5 nM,

101 The rapid proliferation of new synthetic cannabinoid receptor agonists (SCRAs) has initiated cons

102 Synthetic cannabinoid receptor agonists (SCRAs), termed "Spice" or

103 esent study demonstrates that the endogenous cannabinoid receptor agonists 2-arachidonoylglycerol (2-

104 Notably, cannabinoid receptor agonists as well as inhibitors of e

105 Cannabinoid receptor agonists have gained attention as p

106 ion of central nervous system (CNS)-excluded cannabinoid receptor agonists to test the hypothesis tha

107 ed the effects and mechanism(s) of action of cannabinoid receptor agonists, including Delta9-THC, on

108 full selectivity for the nonpsychotropic CB2 cannabinoid receptor and with efficacy in inducing death

109 describe the subcellular localization of CB1 cannabinoid receptors and eCB synthetic machinery at glu

110 an endogenous signaling system consisting of cannabinoid receptors and endogenous cannabinoids as wel

111 gnaling system, comprising G protein-coupled cannabinoid receptors and their endogenous lipid-derived

112 transporter 3 (VGLUT3)/cholecystokinin/CB(1) cannabinoid receptor(+) and neuropeptide Y(+) local-circ

113 , as shown by its failure to bind to the CB1 cannabinoid receptor, and has no activity in CB2-deficie

114 tein-coupled receptor (GPR) 55 is a putative cannabinoid receptor, and l-alpha-lysophosphatidylinosit

115 GPR55 is a putative cannabinoid receptor, and l-alpha-lysophosphatidylinosit

116 t (LA) but not affected by administration of cannabinoid receptor antagonist (AM251).

117 A cannabinoid receptor antagonist significantly increased

118 This burst firing was suppressed by a cannabinoid receptor antagonist.

119 f the acetaminophen metabolite AM 404 and of cannabinoid receptor antagonists as well as data from ti

120 eatment with the peripherally restricted CB1 cannabinoid receptor antagonists, AM6546 and URB447.

121 Cannabinoid receptors are distributed in multiple tissue

122 Cannabinoid receptors are functionally operant at both g

123 rs are present in the nervous system and CB2 cannabinoid receptors are in the immune system, recent e

124 obilization and consequent activation of CB1 cannabinoid receptors are necessary and sufficient to ex

125 The most abundant cannabinoid receptors are the CB1 cannabinoid receptors;

126 lucose-feedback sensor) and CNR2 (encoding a cannabinoid receptor) as central effectors of B-lymphoid

127 nfirm structures of three mutants of the CB1 cannabinoid receptor associated with different functions

128 d differences in regional benzodiazepine and cannabinoid receptor binding site expression.

129 Type 1 cannabinoid receptor blockers increase high-density lipo

130 oposed that OX(1) orexin receptors and CB(1) cannabinoid receptors can form heteromeric complexes, wh

131 potential recordings has shown that central cannabinoid receptor (cannabinoid receptor type 1) agoni

132 eport that solubilization of a GPCR, type II cannabinoid receptor CB(2), in a Facade detergent enable

133 activity of HER2: heteromerization with the cannabinoid receptor CB(2)R.

134 ugh it shares low sequence homology with the cannabinoid receptors CB(1)R and CB(2)R, a growing body

135 reduced availability of the cerebral type 1 cannabinoid receptor (CB(1)R) in manifest HD.

136 egulators of MC biology, we investigated how cannabinoid receptor (CB) 1 signaling affects human muco

137 Cannabinoid receptor (CB)(2) is an immune cell-localized

138 Because activation of CB(1) cannabinoid receptors (CB(1)R) induces vasodilation and

139 This was replicated by inhibition of cannabinoid receptors (CB(1)R), suggesting a role for en

140 bitory effects demonstrated by activation of cannabinoid receptors (CB) on cancer proliferation and m

141 s are mediated through at least two distinct cannabinoid receptors (CB), CB1 and CB2.

142 o adrenergic receptors alpha1 and alpha2 and cannabinoid receptor CB1, but had no effect in nuclear r

143 An allosteric ligand for the cannabinoid receptor CB1, Org 27569, exhibits an intrigu

144 oylethanolamine (anandamide), which activate cannabinoid receptors CB1 and CB2 in the nervous system

145 l processes mainly through the activation of cannabinoid receptors CB1 and CB2.

146 Agonism of the cannabinoid receptors CB1/2 significantly reduces IOP cl

147 Modulation of type 1 cannabinoid receptor (CB1) activity has been touted as a

148 thanolamine), was shown to bind to the human cannabinoid receptor (CB1) and activate intracellular si

149 uronal cell loss in HD, levels of the type 1 cannabinoid receptor (CB1) decrease in the basal ganglia

150 long (D2L) switches the signaling of type 1 cannabinoid receptor (CB1) from Galphai to Galphas, a pr

151 term, plasticity of GABA release from type 1 cannabinoid receptor (CB1)-expressing axons.

152 ng basket cells, axoaxonic cells, and type 1 cannabinoid receptor (CB1)-expressing basket cells, whic

153 CB1 cannabinoid receptors (CB1) are located at axon terminal

154 n the brain, endocannabinoids act via Type 1-cannabinoid receptors (CB1) to modulate synaptic transmi

155 19-null animals by the expression of a human cannabinoid receptor, CB1, highlighting the orthology of

156 THC), was isolated in the mid-1960s, but the cannabinoid receptors, CB1 and CB2, and the major endoge

157 Mice deficient in cannabinoid receptors, CB1 and CB2, show compromised PDZ

158 lant psychoactive constituent, activate both cannabinoid receptors, CB1 and CB2.

159 noids are primarily mediated by two types of cannabinoid receptors, CB1 receptors in the nervous syst

160 y human ECs from multiple organs express the cannabinoid receptors CB1R, GPR18, and GPR55, as well as

161 primes the recruitment of beta cells by CB1 cannabinoid receptor (CB1R) engagement.

162 Involvement of the type 1 cannabinoid receptor (CB1R) in the effects of alcohol on

163 but molecular effectors downstream of type-1 cannabinoid receptor (CB1R)-activation remain incomplete

164 us, in vivo inhibition of MAGL induces a CB1 cannabinoid receptor (CB1R)-dependent suppression of inh

165 on terminals that express the primary type 1 cannabinoid receptor (CB1R); 3) binds to CB1R, which inh

166 rebellum of mice with global loss of the CB1 cannabinoid receptor (CB1R, Cb1(-/-) mice) and in mice l

167 Activation of type 1 cannabinoid receptors (CB1R) decreases GABA and glutamat

168 ease of endocannabinoids that bind to type 1 cannabinoid receptors (CB1R) located on synaptic termina

169 s a transient window when the dominant brain cannabinoid receptor, CB1R, is expressed on afferent ter

170 s on type 1 orexin receptors (OX1Rs), type 1 cannabinoid receptors (CB1Rs) and diacylglycerol lipase

171 CB1 cannabinoid receptors (CB1Rs) are attractive therapeutic

172 Type 1 cannabinoid receptors (CB1Rs) are widely expressed in th

173 We investigated in mice the role of CB1 cannabinoid receptors (CB1Rs) in memory impairment and s

174 yl-D-aspartate receptors (NMDARs) and type 1 cannabinoid receptors (CB1Rs) induces LTD at the first c

175 beta Cells express CB1 cannabinoid receptors (CB1Rs), and the enzymatic machine

176 engers that, by targeting presynaptic type 1 cannabinoid receptors (CB1Rs), mediate short- and long-t

177 Cannabinoid receptor CB2 (CB2(-/-)) mice were used as a

178 The cannabinoid receptor CB2 is predominately expressed in t

179 t, upon simultaneous ex-pression of GDE3 and cannabinoid receptor CB2, 2-acyl LPI evoked the same sig

180 itionally, we found that capsaicin increased cannabinoid receptor (CB2) in the cochlea, which leads t

181 port agonist-bound cryo-EM structures of the cannabinoid receptor, CB2, in complex with Gi.

182 Expression of CB2 cannabinoid receptor (CB2R) and Il1b mRNA was increased

183 at may enhance intravenous SA of THC and the cannabinoid receptor (CBR) agonist CP 55 940 in Old Worl

184 The direct activation of cannabinoid receptors (CBRs) results in several benefici

185 control over neuronal activity by activating cannabinoid receptors (CBRs).

186 s unknown, as is the potential modulation by cannabinoid receptors (CBRs).

187 ral precision of signaling at neuronal CB(1) cannabinoid receptors, chiefly deregulating Stat3-depend

188 trate that genetic or chemical inhibition of cannabinoid receptor (Cnr) activity disrupts liver devel

189 s callosum enlargement due to the errant CB1 cannabinoid receptor-containing corticofugal axon spread

190 at absorption, and feeding behavior in CB(1) cannabinoid receptor-deficient mice.

191 nyl)ethyl amide (WOBE437) exerted pronounced cannabinoid receptor-dependent anxiolytic, antiinflammat

192 verses the stress-induced anxiety state in a cannabinoid receptor-dependent manner.

193 glycerol (2-AG) to regulate certain forms of cannabinoid receptor-dependent signaling in the nervous

194 tein, and the inactivation of DAGLs disrupts cannabinoid receptor-dependent synaptic plasticity and i

195 n the brain of MKO(GFAP) mice does not cause cannabinoid receptor desensitization as previously obser

196 creased social play, but blockade of NAc CB1 cannabinoid receptors did not antagonize the play-enhanc

197 Although genetic variation in the type 1 cannabinoid receptor--encoded by the CNR1 gene--is known

198 pid mediators include endogenous agonists of cannabinoid receptors (endocannabinoids), lipid-amide ag

199 The ECS comprises cannabinoid receptors, endogenous cannabinoids (endocann

200 docannabinoid system, comprising CB1 and CB2 cannabinoid receptors, endogenous cannabinoids (endocann

201 oids, suggesting that they arise from type 1 cannabinoid receptor-expressing (CB1R+) interneurons - m

202 re provides an atomic framework for studying cannabinoid receptor function, and will aid the design a

203 ve blockade or inverse agonism of the type 1 cannabinoid receptor has been tested for the improvement

204 In particular, CB(2) cannabinoid receptors have been shown to promote NP prol

205 The cannabinoid receptors have been the targets of intensive

206 Cannabinoid receptors have gained increasing attention a

207 s of regular cannabis users, particularly in cannabinoid receptor-high areas, which are vulnerable to

208 t abundant cannabinoid receptors are the CB1 cannabinoid receptors; however, CB2 cannabinoid receptor

209 ions emerged across regions that are high in cannabinoid receptors (i.e., hippocampus, prefrontal cor

210 G) and anandamide (AEA) activate a canonical cannabinoid receptor in Caenorhabditis elegans and also

211 The function of the CB2 cannabinoid receptor in the brain has long been a matter

212 e potential to interact therapeutically with cannabinoid receptors in addition to its primary PPAR ta

213 ass of lipid-derived mediators that activate cannabinoid receptors in many cells of the body - are ke

214 system (CNS) and the functionality of type-1 cannabinoid receptors in neurons is well documented.

215 The roles of CB1 cannabinoid receptors in regulating neuronal activity ha

216 n of the involvement of endocannabinoids and cannabinoid receptors in skeletal muscle cell differenti

217 social play increased phosphorylation of CB1 cannabinoid receptors in the amygdala.

218 Cannabinoid receptors in the BLA contribute to anxiogene

219 udy reveals a novel cellular function of CB2 cannabinoid receptors in the hippocampus and provides in

220 wledge on the expression and distribution of cannabinoid receptors in the monkey retina, although fur

221 e endocannabinoids and their target, the CB1 cannabinoid receptor, in the adaptation of the brain to

222 ing the allosteric binding site on the CB(1) cannabinoid receptor, in which a CF(3) group successfull

223 uced A-type potassium current (IA) through a cannabinoid receptor-independent mechanism mimicked by a

224 The Cannabinoid Receptor Interacting Protein 1 (Cnrip1) was

225 Cannabinoid receptor interacting protein 1a (CRIP1a) is

226 Cannabinoid receptor-interacting protein 1a (CRIP1a) bin

227 vidence for marked functional selectivity of cannabinoid receptor internalization.

228 forms of LTD were completely absent in CB(1) cannabinoid receptor knock-out mice, whereas pharmacolog

229 s identified as an example of a new class of cannabinoid receptor ligand and allosteric modulator, wi

230 he present study demonstrates that mammalian cannabinoid receptor ligands activate a conserved cannab

231 Here we profile a number of cannabinoid receptor ligands and provide evidence for ma

232 To study cannabinoid receptor ligands, we have developed a novel

233 t enhancement of anandamide signaling at CB1 cannabinoid receptors localized on sensory nerve endings

234 avioral studies in mice, we demonstrate that cannabinoid receptors mediate acute anxiolysis and analg

235 By discussing the mechanisms of cannabinoid receptor-mediated signaling events at critic

236 ovalent probes with high affinities for both cannabinoid receptors, namely, the electrophilic isothio

237 oid signaling system mediated by a canonical cannabinoid receptor, NPR-19, with orthology to human CB

238 ized by their strong expression of the CB(1) cannabinoid receptor, oval/round soma, apical nucleus, a

239 ic and pharmacological manipulation of CB(1) cannabinoid receptors permanently alters cholinergic pro

240 associated metabolic enzymes, together with cannabinoid receptors, predominantly the cannabinoid CB1

241 ase of GABA release upon activation of these cannabinoid receptors remain elusive.

242 Notably, cannabinoid receptors serve as molecular targets for the

243 Studies have shown that disruption of cannabinoid receptor signaling reduces operant responses

244 n chemical cross-linking strategy to map the cannabinoid receptor subtype 2 (CB2)-Galphai interface a

245 The activation of cannabinoid receptor subtype 2 (CB2R) prevents acinar ce

246 The cannabinoid receptor subtype 2 (CB2R) represents an inte

247 itor tacrine and a benzimidazole-based human cannabinoid receptor subtype 2 (hCB(2)R) agonist and inv

248 e hippocampus and provides insights into how cannabinoid receptor subtypes diversify the roles of can

249 th unforeseen opposite allosteric effects on cannabinoid receptors, suggests its potential role in pe

250 Marijuana (MJ) acutely acts on cannabinoid receptors that are found in numerous brain r

251 The CB1 cannabinoid receptor, the main molecular target of endoc

252 The CB1 cannabinoid receptor, the main target of Delta(9)-tetrah

253 ive constituent of cannabis binds to the CB1 cannabinoid receptor, the present study was designed to

254 A-derived endocannabinoids desensitize CB(1) cannabinoid receptors, thus inducing epigenetic repressi

255 that determine the sign of the modulation by cannabinoid receptors to differentially regulate excitat

256 wing cell-autonomous 2-AG signaling at CB(1) cannabinoid receptors to persist at atypical locations t

257 neurons and act retrogradely on presynaptic cannabinoid receptors to potentiate the locomotor freque

258 the CB1 cannabinoid receptors; however, CB2 cannabinoid receptors, transient receptor potential chan

259 Cannabinoid receptor transmission strongly influences em

260 Experiments with cannabinoid receptor type 1 (CB(1))/MGL double-KO mice r

261 - or heterooligomerization between the GPCRs cannabinoid receptor type 1 (CB(1)R) and 5-hydroxytrypta

262 9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB(1)R) inverse agonist (SR

263 tivity of peripheral tissues are mediated by cannabinoid receptor type 1 (CB1) and the central nervou

264 Some inverse agonists of cannabinoid receptor type 1 (CB1) have been demonstrated

265 xiolytic, and neuroprotective efficacies via cannabinoid receptor type 1 (CB1) or type 2 (CB2) or via

266 e evaluated the relationship between in vivo cannabinoid receptor type 1 (CB1) receptor availability

267 duced neuronal maturation, downregulation of cannabinoid receptor type 1 (CB1) receptors, and impaire

268 mpact of such changes on endocannabinoid and cannabinoid receptor type 1 (CB1)-mediated modulation of

269 with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory effect

270 The cannabinoid receptor type 1 (CB1R) colocalized with TRPV

271 The presence of the cannabinoid receptor type 1 (CB1R) has been largely docu

272 e potential role of endocannabinoids and the cannabinoid receptor type 1 (CB1R) in neonatal neurodege

273 ge, contains among the highest expression of cannabinoid receptor type 1 (CB1r) in the brain.

274 preclinical models, peripherally restricted cannabinoid receptor type 1 (CB1R) inhibitors, which are

275 ness of purposeful movements was reverted by cannabinoid receptor type 1 (CB1r) manipulations directl

276 xpress both OX-A receptor type 1 (OX-1R) and cannabinoid receptor type 1 (CB1R) on the plasma membran

277 Cannabinoid receptor type 1 (CB1R) plays a critical role

278 CRs: the alpha2A-adrenergic receptor, GABAB, cannabinoid receptor type 1 (CB1R), and dopamine recepto

279 hibitory synaptic transmission in the PL via cannabinoid receptor type 1 (CB1R)- and 2-arachidonoylgl

280 ent report, we aimed to further evaluate the cannabinoid receptor type 1 (CB1R)-mediated mechanisms i

281 ved vehicle, arachidonyl-2-chloroethylamide (cannabinoid receptor type 1 [CB(1) ] agonist), JWH-015 (

282 ng acute hippocampal slices, and hippocampal cannabinoid receptor type 1 and brain-derived neurotroph

283 is factor (TNF)-induced transcription of the cannabinoid receptor type 1 gene in primary fetal striat

284 fatty acid amide hydrolase(-/-) mice, and in cannabinoid receptor type 1(-/-) (CB1-/-) and cannabinoi

285 has shown that central cannabinoid receptor (cannabinoid receptor type 1) agonists decrease the power

286 e downregulation of brain cannabinoid CB(1) (cannabinoid receptor type 1) receptors after chronic exp

287 The cannabinoid receptor type 2 (CB2) is a class A GPCR that

288 receptor type 1 [CB(1) ] agonist), JWH-015 (cannabinoid receptor type 2 [CB(2) ] agonist), and AM630

289 strategy identified thienopyrimidine 12 as a cannabinoid receptor type 2 agonist (hCB2) with moderate

290 Expression of cannabinoid receptor Type 2 was reported in osteoblasts

291 annabinoid receptor type 1(-/-) (CB1-/-) and cannabinoid receptor type 2(-/-) (CB2-/-).

292 her putative Delta9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GP

293 compound binds to CB1 more selectively than cannabinoid receptor type 2, with a Ki value of 220 nM.

294 Cannabinoid receptor type-1 (CB1) is known to have a sub

295 Cannabinoid receptor type-1 (CB1) plays a crucial role i

296 t subpopulation of NAc FSIs that express the cannabinoid receptor type-1 (CB1).

297 Cannabinoid receptors type 2 (CB2) represent a target wi

298 Potential therapeutic targets include the cannabinoid receptors, type 1 and 2, as well as biosynth

299 CB(1) and CB(2) cannabinoid receptors undergo internalization after sust

300 Cannabinoid receptors, which mediate the actions of cann